Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
This study is looking at a medicine called Bosutinib for children and teenagers aged 1 to 17 who have a type of blood cancer called Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML). This includes those newly diagnosed and those whose CML hasn't responded well to previous treatments or who couldn't tolerate them. The main goals are to figure out the best dose of Bosutinib for children, see how safe it is, and check if it helps treat their CML. Researchers will also learn how the body handles the medicine. The study will involve hospitals internationally, and it's designed to gather important information to help children with this condition.
A colpo d'occhio
Di cosa tratta questo studio?
This research study is about a medicine called Bosutinib, which is being tested for children and teenagers between 1 and 17 years old who have Chronic Myeloid Leukemia (CML). CML is a type of blood cancer, and 'Philadelphia chromosome-positive' means it has a specific genetic change. The study involves two main groups: those recently diagnosed with CML, and those whose CML has either not responded well to other treatments (called 'resistant') or who couldn't continue other treatments because of side effects (called 'intolerant').
The study has two phases. In the first phase, doctors will carefully increase the dose of Bosutinib to find the safest and most effective amount for children, similar to the dose that works for adults. They will also look at how children's bodies react to the medicine. The second phase will then use this recommended dose to see how well it works and how safe it is for a larger group of children with CML.
Finding new and effective treatments for children with CML is very important. This study helps move us closer to understanding if Bosutinib can be a good treatment option for this specific group of patients, particularly those who might not have responded well to other medicines in the past. The goal is to improve the health and well-being of young people living with CML.
Punti chiave
- This study is for children and teenagers (1-17) with Philadelphia chromosome-positive CML.
- It is testing a medicine called Bosutinib.
- It includes those newly diagnosed, or those who didn't respond to previous treatments, or couldn't tolerate them.
- The study aims to find the right dose, safety, and effectiveness of Bosutinib in young people.
- Regular hospital visits and tests will be part of taking part.
Chi può essere idoneo?
To join the first part of this study, participants must be between 1 and 17 years old. They need to have Philadelphia chromosome-positive CML that has either not responded well to at least one previous medicine (called a TKI) or they couldn't tolerate that previous medicine due to difficult side effects. We need to be sure of the CML diagnosis using specific blood and bone marrow tests.
If you're unable to take other CML medicines because of side effects, you might still be able to join, even if those medicines were working well. The doctors will decide if your side effects were significant enough to consider you for this study.
Later in the study, participants will also include those who have recently been diagnosed with CML and haven't had other treatments yet, as well as those with more advanced stages of CML (called accelerated or blast phase), provided they also have the Philadelphia chromosome and resistance or intolerance to previous treatments.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you between 1 and 17 years old?
- Do you have Philadelphia chromosome-positive CML?
- Has your CML not responded well to previous treatments, or did you have significant side effects from them?
- Are you willing to have regular blood tests and bone marrow checks?
Cosa comporta la partecipazione?
If you decide to take part, the study will involve regular visits to the hospital. Doctors will perform tests, including blood tests and bone marrow checks, to monitor your CML and how you're responding to the Bosutinib. You'll take Bosutinib medicine by mouth once a day.
The study will carefully track any side effects you might experience and how the medicine works in your body. The overall length of time you'll be in the study will depend on how you respond to the treatment and your individual situation, but it will involve ongoing check-ups. The doctors and nurses will explain the full schedule of visits and assessments if you are considered for the study.
Rischi e benefici potenziali
Locations (59)
- Children's Hospital of AlabamaCodice postale verificatoBirmingham, Stati Uniti
- Phoenix Childrens HospitalCodice postale verificatoPhoenix, Stati Uniti
- Arkansas Children's HospitalCodice postale verificatoLittle Rock, Stati Uniti
- Kaiser Permanente Downey Medical CenterCodice postale verificatoDowney, United States
- Loma Linda University Medical CenterCodice postale verificatoLoma Linda, United States
- Kaiser Permanene-OaklandCodice postale verificatoOakland, Stati Uniti
- Children's Hospital of Orange CountyCodice postale verificatoOrange, Stati Uniti
- Lucile Packard Children's Hospital Stanford UniversityCodice postale verificatoPalo Alto, Stati Uniti
- Alfred I duPont Hospital for ChildrenCodice postale verificatoWilmington, United States
- Golisano Children's Hospital of Southwest FloridaCodice postale verificatoFort Myers, Stati Uniti
- University of Florida Health Science Center - GainesvilleCodice postale verificatoGainesville, Stati Uniti
- Nemours Children's HospitalCodice postale verificatoOrlando, Stati Uniti
Domande comuni
Che cos'è CML?
CML stands for Chronic Myeloid Leukemia, a type of cancer that starts in the blood-forming cells of the bone marrow. 'Philadelphia chromosome-positive' means there's a specific genetic change in the cancer cells.
What is Bosutinib?
Bosutinib is a medicine being studied as a treatment for CML. It's a type of drug called a 'tyrosine kinase inhibitor' (TKI), which works by blocking signals that help cancer cells grow.
What does 'resistant' or 'intolerant' mean?
If your CML is 'resistant,' it means previous treatments haven't worked well enough. If you are 'intolerant,' it means you had severe side effects from previous CML medicines and couldn't continue taking them.
Will I get a placebo (dummy medicine)?
No, this study does not use a placebo. All participants will receive Bosutinib, the study medication.
Per quanto tempo sarò nello studio?
The study will involve ongoing treatment and check-ups. The exact duration for you will depend on your response to the treatment and what your doctor advises.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.